Literature DB >> 3489075

Evaluation of evoked potentials and lymphocyte subsets as possible markers of multiple sclerosis: one year follow up of 30 patients.

A Ghezzi, M Zaffaroni, D Caputo, R Montanini, C L Cazzullo.   

Abstract

Evoked potentials and T-lymphocyte helper/suppressor ratio (H/S) were evaluated serially together with neurological status in 30 definite multiple sclerosis patients to evaluate their possible role in monitoring disease progression. Evoked potentials in many cases reflected the clinical status of the pathways tested, but some exceptions were observed, probably due to subclinical relapses or physical factors. In some instances the occurrence of subclinical relapses was suggested by increased H/S ratios. Serial H/S values increased in parallel with clinical and subclinical relapses, and seemed to show specific patterns in relation to the type of clinical course (relapsing, stable, chronic progressive). Our results suggest that evoked potentials and H/S ratio serial analysis can contribute to a better assessment of the progress of multiple sclerosis.

Entities:  

Mesh:

Year:  1986        PMID: 3489075      PMCID: PMC1028953          DOI: 10.1136/jnnp.49.8.913

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

Review 1.  The design of clinical studies to assess therapeutic efficacy in multiple sclerosis.

Authors:  J R Brown; G W Beebe; J F Kurtzke; R B Loewenson; D H Silberberg; W W Tourtellotte
Journal:  Neurology       Date:  1979-09       Impact factor: 9.910

2.  The occurrence, specificity, and role of neuroelectric blocking factors in multiple sclerosis.

Authors:  C L Schauf; F A Davis
Journal:  Neurology       Date:  1978-09       Impact factor: 9.910

3.  Changes in visual and short-latency somatosensory evoked potentials in patients with multiple sclerosis.

Authors:  A W de Weerd; E J Jonkman
Journal:  Adv Neurol       Date:  1982

4.  The value of sequential evoked potential recordings in multiple sclerosis patients.

Authors:  M Kjaer
Journal:  Adv Neurol       Date:  1982

5.  Clinicopathological correlations in multiple sclerosis and related diseases.

Authors:  S G Waxman
Journal:  Adv Neurol       Date:  1981

6.  Exacerbations, activity, and progression in multiple sclerosis.

Authors:  C M Poser
Journal:  Arch Neurol       Date:  1980-08

7.  Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies.

Authors:  E L Reinherz; H L Weiner; S L Hauser; J A Cohen; J A Distaso; S F Schlossman
Journal:  N Engl J Med       Date:  1980-07-17       Impact factor: 91.245

8.  Lymphocyte subpopulations in patients with multiple sclerosis.

Authors:  A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-02       Impact factor: 10.154

9.  Immunoregulatory T-cells and lymphocytotoxic antibodies in active multiple sclerosis: weekly analysis over a six-month period.

Authors:  S L Hauser; E L Reinherz; C J Hoban; S F Schlossman; H L Weiner
Journal:  Ann Neurol       Date:  1983-04       Impact factor: 10.422

10.  Comparative study of visual evoked potentials in spinocerebellar ataxias and multiple sclerosis.

Authors:  A Ghezzi; R Montanini
Journal:  Acta Neurol Scand       Date:  1985-03       Impact factor: 3.209

View more
  7 in total

1.  Serial studies of evoked potentials and circulating lymphocyte subsets for multiple sclerosis: attempts to monitor progress.

Authors:  H M Chapel; M Small; S Gregory; W B Matthews
Journal:  J Neurol       Date:  1990-08       Impact factor: 4.849

2.  Isolated optic neuritis and its prognosis for multiple sclerosis: a clinical and paraclinical study with evoked potentials. CSF examination and brain MRI.

Authors:  A Ghezzi; V Torri; M Zaffaroni
Journal:  Ital J Neurol Sci       Date:  1996-10

3.  Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study.

Authors:  L Leocani; M Rovaris; F M Boneschi; S Medaglini; P Rossi; V Martinelli; S Amadio; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05-30       Impact factor: 10.154

4.  T cell subsets and disease progression after total lymphoid irradiation in chronic progressive multiple sclerosis.

Authors:  R Troiano; C Devereux; J Oleske; T Denny; M Hafstein; G Zito; C Rohowski-Kochan; P C Dowling; S D Cook
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

5.  HLA typing and T-cell subpopulations in multiple sclerosis.

Authors:  M Zaffaroni; M Di Falco; A Ghezzi; L Rizzolo; G Veneroni; S Marforio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154

6.  Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment.

Authors:  L La Mantia; F Riti; C Milanese; A Salmaggi; M Eoli; C Ciano; G Avanzini
Journal:  Ital J Neurol Sci       Date:  1994-10

7.  Presence of T-cell subset abnormalities in newly diagnosed cases of multiple sclerosis and relationship with short-term clinical activity.

Authors:  M Eoli; M Ferrarini; A Dufour; S Heltaj; L Bevilacqua; G Comi; V Cosi; G Filippini; V Martinelli; C Milanese
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.